{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:17:38Z","timestamp":1776431858484,"version":"3.51.2"},"reference-count":100,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,3]]},"DOI":"10.20945\/2359-3997000000522","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T15:31:40Z","timestamp":1664897500000},"source":"Crossref","is-referenced-by-count":5,"title":["Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-581X","authenticated-orcid":false,"given":"Barbara C.","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-2880","authenticated-orcid":false,"given":"Miguel","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7332-9841","authenticated-orcid":false,"given":"Catarina Brasil","family":"d\u2019Alva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2669-4245","authenticated-orcid":false,"given":"Sergio Setsuo","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5724-8096","authenticated-orcid":false,"given":"Narriane Chaves Pereira de","family":"Holanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-7185","authenticated-orcid":false,"given":"Monique Nakayama","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-6113","authenticated-orcid":false,"given":"Vera","family":"Szejnfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6269-2354","authenticated-orcid":false,"given":"Cristiano A. F.","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1262-3486","authenticated-orcid":false,"given":"Francisco Jos\u00e9 Albuquerque de","family":"Paula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-0742","authenticated-orcid":false,"given":"Francisco","family":"Bandeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"issue":"9","key":"key20221004113127_B1","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","unstructured":"Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-34.","journal-title":"Ann Intern Med"},{"issue":"1","key":"key20221004113127_B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S2213-8587(19)30378-X","article-title":"Reducing the treatment gap in osteoporosis","volume":"8","author":"Compston","year":"2020","unstructured":"Compston J. Reducing the treatment gap in osteoporosis. Lancet Diabetes Endocrinol. 2020;8(1):7-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"key20221004113127_B3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0826","article-title":"Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis","volume":"1","author":"Desai","year":"2018","unstructured":"Desai RJ, Mahesri M, Abdia Y, Barberio J, Tong A, Zhang D, et al. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis. JAMA Netw Open. 2018;1(3):e180826.","journal-title":"JAMA Netw Open"},{"issue":"18","key":"key20221004113127_B4","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799-809.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20221004113127_B5","first-page":"105","article-title":"The epidemiology of osteoporosis","volume":"133","author":"Clynes","year":"2020","unstructured":"Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. Br Med Bull. 2020;133(1):105-17.","journal-title":"Br Med Bull"},{"issue":"10122","key":"key20221004113127_B6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","article-title":"Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial","volume":"391","author":"Shepstone","year":"2018","unstructured":"Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391(10122):741-7.","journal-title":"Lancet"},{"issue":"6","key":"key20221004113127_B7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/jbmr.3411","article-title":"Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study","volume":"33","author":"McCloskey","year":"2018","unstructured":"McCloskey E, Johansson H, Harvey NC, Shepstone L, Lenaghan E, Fordham R, et al. Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study. J Bone Miner Res. 2018;33(6):1020-6.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20221004113127_B8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00198-019-05142-z","article-title":"Systematic screening using FRAX\u00ae leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial","volume":"31","author":"Parsons","year":"2020","unstructured":"Parsons CM, Harvey N, Shepstone L, Kanis JA, Lenaghan E, Clarke S, et al. Systematic screening using FRAX\u00ae leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporos Int. 2020;31(1):67-75.","journal-title":"Osteoporos Int"},{"issue":"2","key":"key20221004113127_B9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00198-019-05226-w","article-title":"Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis","volume":"31","author":"Merlijn","year":"2020","unstructured":"Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int. 2020;31(2):251-7.","journal-title":"Osteoporos Int"},{"key":"key20221004113127_B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update","volume":"26","author":"Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, et al. American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46.","journal-title":"Endocr Pract"},{"issue":"1","key":"key20221004113127_B11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.","journal-title":"Arch Osteoporos"},{"issue":"5","key":"key20221004113127_B12","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-622.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20221004113127_B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E, Bruy\u00e8re O, Veronese N, Lorentzon M, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1-12.","journal-title":"Osteoporos Int"},{"issue":"3","key":"key20221004113127_B14","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update","volume":"105","author":"Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020;105(3).","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20221004113127_B15","first-page":"331","article-title":"Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?","volume":"64","author":"Bandeira","year":"2020","unstructured":"Bandeira F, Dantas W, Bilezikian JP. Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates? Arch Endocrinol Metab. 2020;64(4):331-6.","journal-title":"Arch Endocrinol Metab"},{"issue":"10117","key":"key20221004113127_B16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in postmenopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230-40.","journal-title":"Lancet"},{"issue":"15","key":"key20221004113127_B17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417-27.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20221004113127_B18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis","volume":"32","author":"Cosman","year":"2017","unstructured":"Cosman F, Nieves JW, Dempster DW. Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. J Bone Miner Res. 2017;32(2):198-202.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key20221004113127_B19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials","volume":"34","author":"Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, et al. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. J Bone Miner Res. 2019;34(4):632-42.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"key20221004113127_B20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","article-title":"Imminent risk of fracture after fracture","volume":"28","author":"Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC, Od\u00e9n A, Gudnason V, McCloskey E, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28(3):775-80.","journal-title":"Osteoporos Int"},{"issue":"4","key":"key20221004113127_B21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.297.4.387","article-title":"Risk of subsequent fracture after low-trauma fracture in men and women","volume":"297","author":"Center","year":"2007","unstructured":"Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297(4):387-94.","journal-title":"JAMA"},{"issue":"6","key":"key20221004113127_B22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/jbmr.35","article-title":"Time since prior fracture is a risk modifier for 10-year osteoporotic fractures","volume":"25","author":"Giangregorio","year":"2010","unstructured":"Giangregorio LM, Leslie WD. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res. 2010;25(6):1400-5.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"key20221004113127_B23","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-006-0125-y","article-title":"Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study","volume":"17","author":"Nymark","year":"2006","unstructured":"Nymark T, Lauritsen JM, Ovesen O, R\u00f6ck ND, Jeune B. Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int. 2006;17(9):1353-7.","journal-title":"Osteoporos Int"},{"issue":"1","key":"key20221004113127_B24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ard.2008.092775","article-title":"Clinical subsequent fractures cluster in time after first fractures","volume":"68","author":"van Geel","year":"2009","unstructured":"van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68(1):99-102.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"key20221004113127_B25","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00198-010-1178-5","article-title":"Risk of subsequent fracture and mortality within 5 years after a nonvertebral fracture","volume":"21","author":"Huntjens","year":"2010","unstructured":"Huntjens KM, Kosar S, van Geel TA, Geusens PP, Willems P, Kessels A, et al. Risk of subsequent fracture and mortality within 5 years after a nonvertebral fracture. Osteoporos Int. 2010;21(12):2075-82.","journal-title":"Osteoporos Int"},{"issue":"8","key":"key20221004113127_B26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.otsr.2014.09.017","article-title":"Burden of proximal humerus fractures in the French National Hospital Database","volume":"100","author":"Maravic","year":"2014","unstructured":"Maravic M, Briot K, Roux C. Burden of proximal humerus fractures in the French National Hospital Database. Orthop Traumatol Surg Res. 2014;100(8):931-4.","journal-title":"Orthop Traumatol Surg Res"},{"issue":"3","key":"key20221004113127_B27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2106\/JBJS.G.01529","article-title":"Proximal humeral fracture as a risk factor for subsequent hip fractures","volume":"91","author":"Clinton","year":"2009","unstructured":"Clinton J, Franta A, Polissar NL, Neradilek B, Mounce D, Fink HA, et al. Proximal humeral fracture as a risk factor for subsequent hip fractures. J Bone Joint Surg Am. 2009;91(3):503-11.","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"key20221004113127_B28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/jbmr.3953","article-title":"History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting With a Fragility Fracture","volume":"35","author":"Toth","year":"2020","unstructured":"Toth E, Banefelt J, \u00c5kesson K, Sp\u00e5ngeus A, Orts\u00e4ter G, Libanati C. History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting With a Fragility Fracture. J Bone Miner Res. 2020;35(5):861-8.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20221004113127_B29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12891-021-04051-9","article-title":"Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada","volume":"22","author":"Adachi","year":"2021","unstructured":"Adachi JD, Brown JP, Schemitsch E, Tarride JE, Brown V, Bell AD, et al. Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. BMC Musculoskelet Disord. 2021;22(1):224.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"key20221004113127_B30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","article-title":"Risk of subsequent fracture after prior fracture among older women","volume":"30","author":"Balasubramanian","year":"2019","unstructured":"Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG, Grauer A, et al. Risk of subsequent fracture after prior fracture among older women. Osteoporos Int. 2019;30(1):79-92.","journal-title":"Osteoporos Int"},{"issue":"11","key":"key20221004113127_B31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-114-11-919","article-title":"Preexisting fractures and bone mass predict vertebral fracture incidence in women","volume":"114","author":"Ross","year":"1991","unstructured":"Ross PD, Davis JW, Epstein RS, Wasnich RD. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114(11):919-23.","journal-title":"Ann Intern Med"},{"issue":"3","key":"key20221004113127_B32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF01623272","article-title":"Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women","volume":"3","author":"Ross","year":"1993","unstructured":"Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int. 1993;3(3):120-6.","journal-title":"Osteoporos Int"},{"issue":"5","key":"key20221004113127_B33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S8756-3282(99)00202-1","article-title":"Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group","volume":"25","author":"Nevitt","year":"1999","unstructured":"Nevitt MC, Ross PD, Palermo L, Musliner T, Genant HK, Thompson DE. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group. Bone. 1999;25(5):613-9.","journal-title":"Bone"},{"issue":"3","key":"key20221004113127_B34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/jbmr.1476","article-title":"Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women","volume":"27","author":"Gehlbach","year":"2012","unstructured":"Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2012;27(3):645-53.","journal-title":"J Bone Miner Res"},{"issue":"7041","key":"key20221004113127_B35","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254-9.","journal-title":"BMJ"},{"issue":"1","key":"key20221004113127_B36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11657-019-0598-x","article-title":"Predictors of imminent nonvertebral fracture in elderly women with osteoporosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos)","volume":"14","author":"Adachi","year":"2019","unstructured":"Adachi JD, Berger C, Barron R, Weycker D, Anastassiades TP, Davison KS, et al. Predictors of imminent nonvertebral fracture in elderly women with osteoporosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos). Arch Osteoporos. 2019;14(1):53.","journal-title":"Arch Osteoporos"},{"issue":"6","key":"key20221004113127_B37","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10129","article-title":"Predictors of Imminent Risk of Nonvertebral Fracture in Older, High-Risk Women: The Framingham Osteoporosis Study","volume":"3","author":"Hannan","year":"2019","unstructured":"Hannan MT, Weycker D, McLean RR, Sahni S, Bornheimer R, Barron R, et al. Predictors of Imminent Risk of Nonvertebral Fracture in Older, High-Risk Women: The Framingham Osteoporosis Study. JBMR Plus. 2019;3(6):e10129.","journal-title":"JBMR Plus"},{"issue":"7","key":"key20221004113127_B38","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-008-0779-8","article-title":"Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women","volume":"20","author":"Lippuner","year":"2009","unstructured":"Lippuner K, Johansson H, Kanis JA, Rizzoli R. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int. 2009;20(7):1131-40.","journal-title":"Osteoporos Int"},{"issue":"4","key":"key20221004113127_B39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jama.2021.0233","article-title":"Anabolic Therapy for Osteoporosis","volume":"326","author":"Ensrud","year":"2021","unstructured":"Ensrud KE, Schousboe JT. Anabolic Therapy for Osteoporosis. JAMA. 2021;326(4):350-1.","journal-title":"JAMA"},{"issue":"1","key":"key20221004113127_B40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11657-016-0280-5","article-title":"Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data","volume":"11","author":"Bonafede","year":"2016","unstructured":"Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D. Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos. 2016;11(1):26.","journal-title":"Arch Osteoporos"},{"issue":"16","key":"key20221004113127_B41","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.2018.3097","article-title":"Interventions to Prevent Falls in Community-Dwelling Older Adults: US Preventive Services Task Force Recommendation Statement","volume":"319","author":"Grossman","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Interventions to Prevent Falls in Community-Dwelling Older Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(16):1696-704.","journal-title":"JAMA"},{"issue":"2","key":"key20221004113127_B42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1519\/00139143-200932020-00005","article-title":"Descriptive analysis of fatal falls of older adults in a Midwestern county in the year 2005","volume":"32","author":"Deprey","year":"2009","unstructured":"Deprey SM. Descriptive analysis of fatal falls of older adults in a Midwestern county in the year 2005. J Geriatr Phys Ther. 2009;32(2):67-72.","journal-title":"J Geriatr Phys Ther"},{"issue":"1","key":"key20221004113127_B43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/jama.297.1.77","article-title":"Will my patient fall?","volume":"297","author":"Ganz","year":"2007","unstructured":"Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ. Will my patient fall? JAMA. 2007;297(1):77-86.","journal-title":"JAMA"},{"issue":"8","key":"key20221004113127_B44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMcp1903252","article-title":"Prevention of Falls in Community-Dwelling Older Adults","volume":"382","author":"Ganz","year":"2020","unstructured":"Ganz DA, Latham NK. Prevention of Falls in Community-Dwelling Older Adults. N Engl J Med. 2020;382(8):734-43.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20221004113127_B45","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/EDE.0b013e3181e89905","article-title":"Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis","volume":"21","author":"Deandrea","year":"2010","unstructured":"Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E. Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology. 2010;21(5):658-68.","journal-title":"Epidemiology"},{"issue":"4","key":"key20221004113127_B46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jclinepi.2009.06.010","article-title":"Quantifying the magnitude of risk for balance impairment on falls in community-dwelling older adults: a systematic review and meta-analysis","volume":"63","author":"Muir","year":"2010","unstructured":"Muir SW, Berg K, Chesworth B, Klar N, Speechley M. Quantifying the magnitude of risk for balance impairment on falls in community-dwelling older adults: a systematic review and meta-analysis. J Clin Epidemiol. 2010;63(4):389-406.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"key20221004113127_B47","doi-asserted-by":"crossref","first-page":"589.e5","DOI":"10.1016\/j.jamda.2018.11.003","article-title":"Orthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis","volume":"20","author":"Mol","year":"2019","unstructured":"Mol A, Bui Hoang PTS, Sharmin S, Reijnierse EM, van Wezel RJA, Meskers CGM, et al. Orthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis. J Am Med Dir Assoc. 2019;20(5):589-97.e5.","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"key20221004113127_B48","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/jgs.12209","article-title":"Depressive symptomatology as a risk factor for falls in older people: systematic review and meta-analysis","volume":"61","author":"Kvelde","year":"2013","unstructured":"Kvelde T, McVeigh C, Toson B, Greenaway M, Lord SR, Delbaere K, et al. Depressive symptomatology as a risk factor for falls in older people: systematic review and meta-analysis. J Am Geriatr Soc. 2013;61(5):694-706.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"key20221004113127_B49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/afs012","article-title":"The role of cognitive impairment in fall risk among older adults: a systematic review and meta-analysis","volume":"41","author":"Muir","year":"2012","unstructured":"Muir SW, Gopaul K, Montero Odasso MM. The role of cognitive impairment in fall risk among older adults: a systematic review and meta-analysis. Age Ageing. 2012;41(3):299-308.","journal-title":"Age Ageing"},{"issue":"4","key":"key20221004113127_B50","doi-asserted-by":"crossref","first-page":"372.e1","DOI":"10.1016\/j.jamda.2017.12.099","article-title":"Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others","volume":"19","author":"Seppala","year":"2018","unstructured":"Seppala LJ, van de Glind EMM, Daams JG, Ploegmakers KJ, de Vries M, Wermelink A, et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others. J Am Med Dir Assoc. 2018;19(4):372.e1-.e8.","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"key20221004113127_B51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11657-020-00784-7","article-title":"Predictors of imminent risk of fracture in Medicare-enrolled men and women","volume":"15","author":"Yusuf","year":"2020","unstructured":"Yusuf AA, Hu Y, Chandler D, Crittenden DB, Barron RL. Predictors of imminent risk of fracture in Medicare-enrolled men and women. Arch Osteoporos. 2020;15(1):120.","journal-title":"Arch Osteoporos"},{"issue":"1","key":"key20221004113127_B52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","article-title":"A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation","volume":"11","author":"Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV, et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25.","journal-title":"Arch Osteoporos"},{"issue":"9","key":"key20221004113127_B53","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","volume":"23","author":"Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257-76.","journal-title":"Osteoporos Int"},{"issue":"3","key":"key20221004113127_B54","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-017-4341-4","article-title":"FRAX-based intervention and assessment thresholds in seven Latin American countries","volume":"29","author":"Clark","year":"2018","unstructured":"Clark P, Denova-Gutierrez E, Zerbini C, Sanchez A, Messina O, Jaller JJ, et al. FRAX-based intervention and assessment thresholds in seven Latin American countries. Osteoporos Int. 2018;29(3):707-15.","journal-title":"Osteoporos Int"},{"issue":"1","key":"key20221004113127_B55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11657-021-00962-1","article-title":"FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan","volume":"16","author":"Lesnyak","year":"2021","unstructured":"Lesnyak O, Zakroyeva A, Babalyan V, Cazac V, Gabdulina G, Ismailov S, et al. FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan. Arch Osteoporos. 2021;16(1):87.","journal-title":"Arch Osteoporos"},{"issue":"10","key":"key20221004113127_B56","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00198-021-05942-2","article-title":"An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: A report for the National Osteoporosis Guideline Group (NOGG)","volume":"32","author":"Kanis","year":"2021","unstructured":"Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, et al. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: A report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int. 2021;32(10):1951-60.","journal-title":"Osteoporos Int"},{"issue":"8","key":"key20221004113127_B57","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s00198-015-3176-0","article-title":"FRAX-based assessment and intervention thresholds \u2013 an exploration of thresholds in women aged 50 years and older in the UK","volume":"26","author":"McCloskey","year":"2015","unstructured":"McCloskey E, Kanis JA, Johansson H, Harvey N, Oden A, Cooper A, et al. FRAX-based assessment and intervention thresholds \u2013 an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int. 2015;26(8):2091-9.","journal-title":"Osteoporos Int"},{"issue":"8","key":"key20221004113127_B58","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/jbmr.4134","article-title":"Defining Very High Fracture Risk: Is FRAX Fit for Purpose?","volume":"35","author":"Compston","year":"2020","unstructured":"Compston JE, Drake MT. Defining Very High Fracture Risk: Is FRAX Fit for Purpose? J Bone Miner Res. 2020;35(8):1399-403.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"key20221004113127_B59","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00198-020-05815-0","article-title":"Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study","volume":"32","author":"McCloskey","year":"2021","unstructured":"McCloskey EV, Johansson H, Harvey NC, Lorentzon M, Shi Y, Kanis JA. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int. 2021;32(8):1601-8.","journal-title":"Osteoporos Int"},{"issue":"8","key":"key20221004113127_B60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437-47.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"key20221004113127_B61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1507\/endocrj.53.27","article-title":"The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis","volume":"53","author":"Kaji","year":"2006","unstructured":"Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J. 2006;53(1):27-34.","journal-title":"Endocr J"},{"issue":"6","key":"key20221004113127_B62","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","unstructured":"Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993-1000.","journal-title":"J Bone Miner Res"},{"key":"key20221004113127_B63","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/S1297-319X(10)70008-7","article-title":"Defining treatment failure in severe osteoporosis","volume":"77","author":"Confavreux","year":"2010","unstructured":"Confavreux CB, Paccou J, David C, Mehsen N, Leboime A, Thomas T. Defining treatment failure in severe osteoporosis. Joint Bone Spine. 2010;77 Suppl 2:S128-32.","journal-title":"Joint Bone Spine"},{"issue":"12","key":"key20221004113127_B64","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","article-title":"A systematic review of factors affecting medication adherence among patients with osteoporosis","volume":"29","author":"Yeam","year":"2018","unstructured":"Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int. 2018;29(12):2623-37.","journal-title":"Osteoporos Int"},{"issue":"12","key":"key20221004113127_B65","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","unstructured":"Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, et al. Treatment failure in osteoporosis. Osteoporos Int. 2012;23(12):2769-74.","journal-title":"Osteoporos Int"},{"issue":"11","key":"key20221004113127_B66","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","article-title":"Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis","volume":"39","author":"Kaveh","year":"2020","unstructured":"Kaveh S, Hosseinifard H, Ghadimi N, Vojdanian M, Aryankhesal A. Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis. Clin Rheumatol. 2020;39(11):3261-76.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"key20221004113127_B67","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4158\/EP-2019-0596","article-title":"Anabolic Therapy and Optimal Treatment Sequences for Patients with Osteoporosis at High Risk for Fracture","volume":"26","author":"Cosman","year":"2020","unstructured":"Cosman F. Anabolic Therapy and Optimal Treatment Sequences for Patients with Osteoporosis at High Risk for Fracture. Endocr Pract. 2020 Jul;26(7):777-786. doi: 10.4158\/EP-2019-0596.","journal-title":"Endocr Pract"},{"issue":"11","key":"key20221004113127_B68","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","article-title":"A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05","volume":"32","author":"Hagino","year":"2021","unstructured":"Hagino H, Sugimoto T, Tanaka S, Sone T, Nakamura T, Soen S, et al. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int. 2021;32(11):2301-11.","journal-title":"Osteoporos Int"},{"issue":"3","key":"key20221004113127_B69","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz162","article-title":"Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis","volume":"105","author":"Leder","year":"2020","unstructured":"Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. 2020;105(3).","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20221004113127_B70","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial","volume":"92","author":"Cosman","year":"2017","unstructured":"Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, et al. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Mayo Clin Proc. 2017;92(2):200-10.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"key20221004113127_B71","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis","volume":"103","author":"Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949-57.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key20221004113127_B72","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","unstructured":"Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012;23(8):2141-50.","journal-title":"Osteoporos Int"},{"issue":"10","key":"key20221004113127_B73","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00198-020-05568-w","article-title":"High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first","volume":"31","author":"Lespessailles","year":"2020","unstructured":"Lespessailles E, Chapurlat R. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first. Osteoporos Int. 2020;31(10):1829-34.","journal-title":"Osteoporos Int"},{"issue":"9","key":"key20221004113127_B74","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra067395","article-title":"Mechanisms of anabolic therapies for osteoporosis","volume":"357","author":"Canalis","year":"2007","unstructured":"Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905-16.","journal-title":"N Engl J Med"},{"issue":"20","key":"key20221004113127_B75","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028-39.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20221004113127_B76","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial","volume":"33","author":"Geusens","year":"2018","unstructured":"Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CA, Minisola S, et al. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. J Bone Miner Res. 2018;33(5):783-94.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"key20221004113127_B77","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/14656566.2020.1721467","article-title":"Treatment options for glucocorticoid-induced osteoporosis","volume":"21","author":"Chiodini","year":"2020","unstructured":"Chiodini I, Merlotti D, Falchetti A, Gennari L. Treatment options for glucocorticoid-induced osteoporosis. Expert Opin Pharmacother. 2020;21(6):721-32.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"key20221004113127_B78","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","unstructured":"Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19(5):745-51.","journal-title":"J Bone Miner Res"},{"issue":"10","key":"key20221004113127_B79","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","unstructured":"Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23(10):1591-600.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"key20221004113127_B80","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis","volume":"104","author":"Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, et al. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. J Clin Endocrinol Metab. 2019;104(5):1623-30.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20221004113127_B81","doi-asserted-by":"crossref","first-page":"101068","DOI":"10.1016\/j.bonr.2021.101068","article-title":"Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study","volume":"14","author":"Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J, et al. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study. Bone Rep. 2021;14:101068.","journal-title":"Bone Rep"},{"key":"key20221004113127_B82","doi-asserted-by":"crossref","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","article-title":"Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"140","author":"Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone. 2020;140:115574.","journal-title":"Bone"},{"issue":"10102","key":"key20221004113127_B83","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585-94.","journal-title":"Lancet"},{"issue":"9999","key":"key20221004113127_B84","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147-55.","journal-title":"Lancet"},{"key":"key20221004113127_B85","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","author":"Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020 Oct 26:dgaa756.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"key20221004113127_B86","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int. 2019;30(12):2437-48.","journal-title":"Osteoporos Int"},{"issue":"16","key":"key20221004113127_B87","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532-43.","journal-title":"N Engl J Med"},{"issue":"19","key":"key20221004113127_B88","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-41.","journal-title":"N Engl J Med"},{"issue":"18","key":"key20221004113127_B89","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-22.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20221004113127_B90","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20221004113127_B91","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/jbmr.3996","article-title":"T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial","volume":"35","author":"Cosman","year":"2020","unstructured":"Cosman F, Lewiecki EM, Ebeling PR, Hesse E, Napoli N, Matsumoto T, et al. T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. J Bone Miner Res. 2020;35(7):1333-42.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"key20221004113127_B92","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study","volume":"34","author":"Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, et al. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2019;34(3):419-28.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"key20221004113127_B93","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(8):672-82.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"key20221004113127_B94","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/jbmr.3722","article-title":"Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment","volume":"34","author":"Ferrari","year":"2019","unstructured":"Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwinski E, et al. Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. J Bone Miner Res. 2019;34(6):1033-40.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key20221004113127_B95","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jocd.2019.07.005","article-title":"Repeating Vertebral Fracture Assessment: 2019 ISCD Official Position","volume":"22","author":"Borges","year":"2019","unstructured":"Borges JLC, Sousa da Silva M, Ward RJ, Diemer KM, Yeap SS, Lewiecki EM. Repeating Vertebral Fracture Assessment: 2019 ISCD Official Position. J Clin Densitom. 2019;22(4):484-8.","journal-title":"J Clin Densitom"},{"issue":"1","key":"key20221004113127_B96","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11657-021-00902-z","article-title":"Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020)","volume":"16","author":"Pereira","year":"2021","unstructured":"Pereira RMR, Perez MO, Paula AP, Moreira C, Castro CHM, Zerbini CAF, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020). Arch Osteoporos. 2021;16(1):49.","journal-title":"Arch Osteoporos"},{"issue":"12","key":"key20221004113127_B97","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Cipriani","year":"2012","unstructured":"Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res. 2012;27(12):2419-28.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"key20221004113127_B98","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1359\/JBMR.051023","article-title":"Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis","volume":"21","author":"Tashjian","year":"2006","unstructured":"Tashjian AH Jr, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006;21(3):354-65.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20221004113127_B99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-020-00652-w","article-title":"Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk","volume":"19","author":"Fixen","year":"2021","unstructured":"Fixen C, Tunoa J. Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk. Curr Osteoporos Rep. 2021;19(1):15-22.","journal-title":"Curr Osteoporos Rep"},{"issue":"8","key":"key20221004113127_B100","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/jcm10081660","article-title":"Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"10","author":"Vestergaard Kvist","year":"2021","unstructured":"Vestergaard Kvist A, Faruque J, Vallejo-Yague E, Weiler S, Winter EM, Burden AM. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med. 2021 Apr 13;10(8):1660.","journal-title":"J Clin Med"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T15:33:10Z","timestamp":1664897590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/definition-and-management-of-very-high-fracture-risk-in-women-with-postmenopausal-osteoporosis-a-position-statement-from-the-brazilian-society-of-endocrinology-and-metabolism-sbem-and-the-brazilian\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":100,"alternative-id":["10.20945\/2359-3997000000522"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000522","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]}}}